Journals / Epilepsi / 2021 / Cilt: 27 - Sayı: 3

Short-Term Results of Vagal Nerve Stimulation in Resistant Epilepsy Patients

Dirençli Epilepsi Hastalarında Vagal Sinir Stimulasyonunun Kısa Dönem Sonuçları

Journal
Epilepsi
Pages
138–143
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although a cumulative effect was reported, we have observed a minimal decrease in frequency after the 3rd month

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Vagal nerve stimulation (VNS) is an appropriate treatment option for refractory patients who are not eligible for resective epilepsy surgery.
📊
Key Findings & Data:Methods: A retrospective survey was performed for patients who were diagnosed as drug resistant epilepsy and underwent VNS implantation, with at least 1 year of follow-up.
💡
Conclusion & Impact:Although a cumulative effect was reported, we have observed a minimal decrease in frequency after the 3rd month
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Vagal nerve stimulation (VNS) is an appropriate treatment option for refractory patients who are not eligible for resective epilepsy surgery. In this study, the clinical and demographic characteristics of VNS patients were documented and it was aimed to determine the effect of VNS on seizure control. Methods: A retrospective survey was performed for patients who were diagnosed as drug resistant epilepsy and underwent VNS implantation, with at least 1 year of follow-up. Nine patients (eight males and one female) with an average age of 30.11 (18–42), were included. Reduction in seizure frequency prior and in the 3rd, 6th, and 12th months after VNS implantation was compared. Patients were considered responders when a reduction of seizures of more than 50% was reported. Results: The mean time from the onset of the disease to VNS implantation was 17.33±9.75 years and the mean age when VNS was implanted was 24.53 (9–39). Decrease in frequency of seizures from VNS implantation to 3 months and 6 months was statistically significant (p=0.003 and p=0.012, respectively). No statistical significance was found between the frequency of seizures before treatment and at the 12th month (p=0.153). Conclusion: In our study, we observed a decrease in seizure frequency in patients with drug resistant epilepsy with a variety of etiologies, which was similar with the literature data. Although a cumulative effect was reported, we have observed a minimal decrease in frequency after the 3rd month

Özet

Amaç: Epilepsi hastaların 1/3’ünün politerapiye rağmen ilaca dirençli olduğu bilinmektedir. Vagal sinir stimulasyonu (VNS) rezektif epilepsi cerrahisine uygun olmayan dirençli hastalarda uygun bir tedavi seçeneğidir. Bu çalışmada, VNS hastalarının klinik ve demografik özellikleri dökümente edilmiş ve VNS’in nöbet kontrolündeki etkisinin belirlenmesi amaçlanmıştır. Gereç ve Yöntem: Hastanemiz epilepsi polikliniğinden VNS implantasyonu sonrası en az 1 yıldır takip edilen, dirençli epilepsi hastalarının verileri retrospektif olarak değerlendirildi. Çalışmaya ortalama yaşı 27.50 (11–42) olan 14 hasta (11 erkek, 3 kadın) dahil edildi.Hastaların demografik dataları, epilepsi etyolojileri, nöbet sıklıkları, nöbet tipleri, kullandıkları ilaçlar dökümente edildi. VNS öncesi ile 3, 6 ve 12. aylardaki nöbet sıkları kıyaslandı. Nöbet sıklığındaki ≥%50 azalma anlamlı kabul edildi. Bulgular: Hastalığın başlangıcından VNS implantasyonuna kadar geçen süre ortalama 17.33±9.75 yıl, VNS takıldığındaki yaş ortalaması 24.53 (9–39) idi. VNS implantasyonundan sonra geçen süre ise ortalama 4.69±3.72 yıl olarak tespit edildi. VNS implantasyonu öncesi hastaların ortalama nöbet sıklıkları 92.8±97.33/ay olarak gözlendi. Tedavi sonrası 3. ay takiplerinde 9 hastanın, 6. ayda 7 hastanın, 12 ayda ise 7 hastanın nöbet sıklığında tedavi öncesine göre %50 ve üzeri azalma tespit edildi. Hastaların 0 ile 3. ay nöbet sıklıkları ve 0 ile 6. ay nöbet sıklıkları değerlendirildiğinde nöbet sıklığındaki azalma, istatistiksel olarak anlamlı bulunmuştur (sırasıyla; p=0.003, p=0.012). Tedavi öncesi ile 12. ay bakıldığında ise nöbet sıklıkları arasında istatistiksel anlamlılık bulunamamıştır (p=0.153). Sonuç: Çalışmamızda literatür ile uyumlu olarak VNS dirençli hastalarda nöbet sıklığını azalttığı gözlenmiştir. Kümülatif bir etkisi olduğu bazı çalışmalarda gösterilmişse de bizim çalışmamızda 6. aydan itibaren bir değişiklik saptanmıştır.

🔖

Cite This Article

ATAKLI, D., GüL, G., DİRİCAN, A. C., EREN, F., GÜL, Z. B. (2022). Short-Term Results of Vagal Nerve Stimulation in Resistant Epilepsy Patients. Epilepsi, Cilt: 27 - Sayı: 3, 138–143. https://ajindex.com/articles/501599

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51(6):1069−77
  2. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011;365(10):919−26
  3. Pérez-Carbonell L, Faulkner H, Higgins S, Koutroumanidis M, Leschziner G. Vagus nerve stimulation for drug-resistant epilepsy. Pract Neurol 2020;20(3):189−98
  4. Englot DJ, Ouyang D, Garcia PA, Barbaro NM, Chang EF. Epilepsy surgery trends in the United States, 1990-2008. Neurology 2012;78(16):1200−6
  5. Morris GL 3rd, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;81(16):1453−9
  6. Bek S, Erdoğan E, Gokcil Z. Vagal sinir stimulasyonu ve hasta seçimi. Epilepsi 2012;18(Suppl 1):63−7
  7. Ben-Menachem E, Hamberger A, Hedner T, Hammond EJ, Uthman BM, Slater J, et al. Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures. Epilepsy Res 1995;20(3):221−7
  8. Majoie HJ, Rijkers K, Berfelo MW, Hulsman JA, Myint A, Schwarz M, et al. Vagus nerve stimulation in refractory epilepsy: effects on pro- and anti-inflammatory cytokines in peripheral blood. Neuroimmunomodulation 2011;18(1):52−6
  9. McHugh JC, Singh HW, Phillips J, Murphy K, Doherty CP, Delanty N. Outcome measurement after vagal nerve stimulation therapy: proposal of a new classification. Epilepsia 2007;48(2):375−8
  10. Morace R, Di Gennaro G, Quarato PP, D’Aniello A, Mascia A, Grammaldo L, et al. Vagal Nerve Stimulation for Drug-Resistant Epilepsy: Adverse Events and Outcome in a Series of Patients with Long-Term Follow-Up. Acta Neurochir Suppl 2017;124:49−52
  11. Elliott RE, Rodgers SD, Bassani L, Morsi A, Geller EB, Carlson C, et al. Vagus nerve stimulation for children with treatment-resistant epilepsy: a consecutive series of 141 cases. J Neurosurg Pediatr 2011;7(5):491−500
  12. Pakdaman H, Amini Harandi A, Abbasi M, Karimi M, Arami MA, Mosavi SA, et al. Vagus nerve stimulation in drug-resistant epilepsy: the efficacy and adverse effects in a 5-year follow-up study in Iran. Neurol Sci 2016;37(11):1773−8
  13. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predict